TitleTet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.
Publication TypeJournal Article
Year of Publication2011
AuthorsMoran-Crusio, Kelly, Reavie Linsey, Shih Alan, Abdel-Wahab Omar, Ndiaye-Lobry Delphine, Lobry Camille, Figueroa Maria E., Vasanthakumar Aparna, Patel Jay, Zhao Xinyang, Perna Fabiana, Pandey Suveg, Madzo Jozef, Song Chunxiao, Dai Qing, He Chuan, Ibrahim Sherif, Beran Miloslav, Zavadil Jiri, Nimer Stephen D., Melnick Ari, Godley Lucy A., Aifantis Iannis, and Levine Ross L.
JournalCancer Cell
Volume20
Issue1
Pagination11-24
Date Published2011 Jul 12
ISSN1878-3686
KeywordsAlleles, Animals, Cell Proliferation, Cell Transformation, Neoplastic, Dioxygenases, DNA-Binding Proteins, Gene Deletion, Gene Knockout Techniques, Gene Silencing, Haploinsufficiency, Hematopoiesis, Hematopoietic Stem Cells, Humans, Leukemia, Myelomonocytic, Chronic, Mice, Myeloid Cells, Proto-Oncogene Proteins
Abstract

<p>Somatic loss-of-function mutations in the ten-eleven translocation 2 (TET2) gene occur in a significant proportion of patients with myeloid malignancies. Although there are extensive genetic data implicating TET2 mutations in myeloid transformation, the consequences of Tet2 loss in hematopoietic development have not been delineated. We report here an animal model of conditional Tet2 loss in the hematopoietic compartment that leads to increased stem cell self-renewal in vivo as assessed by competitive transplant assays. Tet2 loss leads to a progressive enlargement of the hematopoietic stem cell compartment and eventual myeloproliferation in vivo, including splenomegaly, monocytosis, and extramedullary hematopoiesis. In addition, Tet2(+/-) mice also displayed increased stem cell self-renewal and extramedullary hematopoiesis, suggesting that Tet2 haploinsufficiency contributes to hematopoietic transformation in vivo.</p>

DOI10.1016/j.ccr.2011.06.001
Alternate JournalCancer Cell
PubMed ID21723200
PubMed Central IDPMC3194039
Grant ListF31 AG039991 / AG / NIA NIH HHS / United States
/ HHMI / Howard Hughes Medical Institute / United States
F31-AG039991 / AG / NIA NIH HHS / United States
R21 CA141399 / CA / NCI NIH HHS / United States
R01CA149655 / CA / NCI NIH HHS / United States
CA129831 / CA / NCI NIH HHS / United States
R01 CA105129-07 / CA / NCI NIH HHS / United States
R01CA105129 / CA / NCI NIH HHS / United States
P30 CA016087 / CA / NCI NIH HHS / United States
U54 CA143798 / CA / NCI NIH HHS / United States
P30 CA016087-30 / CA / NCI NIH HHS / United States
5 P30CA16087-31 / CA / NCI NIH HHS / United States
R01 CA133379 / CA / NCI NIH HHS / United States
R01CA133379 / CA / NCI NIH HHS / United States
R01 CA129831 / CA / NCI NIH HHS / United States
5P30CA16087-31 / CA / NCI NIH HHS / United States
R21CA141399 / CA / NCI NIH HHS / United States
CA129831-03S1 / CA / NCI NIH HHS / United States
R01 CA149655 / CA / NCI NIH HHS / United States
R01 CA105129 / CA / NCI NIH HHS / United States
R01 CA133379-04 / CA / NCI NIH HHS / United States
1R01CA138234-01 / CA / NCI NIH HHS / United States
R01GM088847 / GM / NIGMS NIH HHS / United States
R01 CA138234 / CA / NCI NIH HHS / United States
U54CA143798-01 / CA / NCI NIH HHS / United States
R01 GM088847 / GM / NIGMS NIH HHS / United States
R01 CA149655-03 / CA / NCI NIH HHS / United States